Get Appointment

    • +(123)-45- 7890

    Novaestiq – a market disruptive aesthetics business,
    led by an industry leading management team


    Strong Basics

    1) Existing scale – Global Market $70bn sales – High Growth & High Margin.

    2) Huge untapped potential – Consumer Penetration still Low @ 5-10%

    3) Heightened consumer focus on Wellness, Beauty, and Healthy Ageing.

    4) New Technologies make procedures more appealing.


    · First to market, naturally cross-linked, non-toxic modified hyaluronic acid (HA) filler technology.

    · 2 Lead Formulations – midface and lips. Additional formulations planned for organic growth.

    · Breakthrough technology – BDDE-free HA filler (world first).

    · Enhanced efficacy, greater durability due to a higher lifting capacity with a low extrusion force. Expected to be longest lasting filler in US market.


    Chairman Humberto Antunes – ex Global CEO Galderma (Nestlé Skin Health).

    CEO Miles Harrison – ex North America CEO Galderma (Nestlé Skin Health).

    – 30+ years in life sciences spanning aesthetics, consumer and prescription.

    – Took share and scaled aesthetics to $820M (tripled in 5 years) and consumer to $515M (doubled in 5 years), taking the US to 51% of Galderma’s world-wide sales.


    Target US launch 2026, US Forecast annual sales Yr 5 = $560m.

    High Margin Delivery (GM @ 90% guaranteed under terms of JV, EBITDA @ 37%).

    High valuation multiples (4.4x – 21.0x sales) for recently launched products, reflect market confidence in segment viability and future growth.

    Based on peer group analysis and unique offering, potential valuation in year 5 of $1.5bn.

    Upside drivers – Disruptive technologies, M&A, expansion into other geographies, acquisition of novel technology for expansion into other product segments.


    Required fund raise of $26.4m to support the clinical development for regulatory approval.

    For further information please contact:

    Jeremy Kelly or Jason Kalik on


    Investing in off-market companies involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Seismic's offerings are targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions.

    View the full Risk warning here.

    Seismic Venture Partners Ltd is an Alternative Investment Fund Manager (AIFM), specialising in growth capital and venture investing and is authorised and regulated by the Financial Conduct Authority under FRN 784448.

    Seismic Venture Partners Ltd is Registered in England & Wales No.09249524.
    The Registered Office address is at No.17 Cosway Street, London NW1 5NR.